Pricing News: Breaking Pricing News, Comments and Articles. - Page: 4

IDS Announces Upgrades to Voice2Dox Speech Recognition System

Release Includes Enhanced Management Console, Time-Saving Personalization Tools IDS today announced updates to Voice2Dox, its speech recognition application and clinical reporting workflow solution. The update incorporates new features for routine management, user personalization and mobility. This release introduces a module for managi...

Alliance Life Sciences Sponsors ISPOR 18th Annual International Meeting, Presents Study Highlighting Optimal Solutions for Pricing Pharmaceuticals

Download “Determining an Optimal Pricing Strategy for international Differential Pricing”; Booth #3068 Alliance

Viewpoints: When A Doctor Should Keep Quiet; 2 Views Of Hospital Pricing; Stem Cell 'Snake Oil'

Los Angeles Times: For A Dying Patient, A Prescription Of Silence In medical school, we were taught not to withhold information from our patients or to be "paternal" in making decisions for them. We internalized the idea that fully informed patients are better equipped to make treatment decisions. And with patients likely to die of their diseases, discussing the prognosis frankly would allow them...

ThromboGenics Business Update

LEUVEN, Belgium, May 16, 2013 /PRNewswire/ -- JETREA® gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million Phase IIa study evaluating JETREA® in wet AMD patients shows 24% VMA resolution rate for JETREA® treated patients, versus 12% for sham injection. This positive trend and safety profile warrant further larg...

AmerisourceBergen Elects Lon R. Greenberg to Its Board of Directors

AmerisourceBergen Corporation (NYSE: ABC) today announced that Lon R. Greenberg, 62, has been elected to its Board of Directors, effective immediately. Mr. Greenberg fills the vacancy created by Charles H. Cotros’s retirement from the Board in February 2013. Mr. Greenberg also joined the Audit and Corporate Responsibility Committee and Finance Committee...

How to succeed in a stakeholder-driven environment

Pharmaceutical companies must supply convincing evidence of a new drug’s value if it is to achieve attractive price and reimbursement levels, according to a report [...]

InspireMD Announces Reimbursement Coverage for MGuard™ Coronary Embolic Protection Stent (EPS) From Brazil's Largest Private Insurer

BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it received reimbursement approval for the MGuard™ Coronary Embolic Protection Stent (EPS) from UNIMED, Brazil's largest private health care insurer. Alan Milinazzo, InspireMD's President and CEO said, "Reimbu...

BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004)

BioInformatics LLC announces the release of their newest market report: The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities. Arlington, VA (PRWEB) May 16, 2013 BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) With barriers to entry low, the number of suppliers in...

InspireMD Announces Reimbursement Coverage for MGuard™ Coronary Embolic Protection Stent (EPS) from Brazil’s Largest Private Insurer

BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it received reimbursement approval for the MGuard™ Coronary Embolic Protection Stent (EPS) from UNIMED, Brazil's largest private health care insurer. Alan Milinazzo, InspireMD's President and...

UCB and IBM Collaborate to Personalize Care for Epilepsy Patients

ARMONK, N.Y. and BRUSSELS, May 16, 2013 /PRNewswire/ -- regulated information -- UCB and IBM (NYSE:IBM) today announced the completion of the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care to people living with epilepsy. The milestone marks the critical first step in the path towards eventually harnessin...

Neuropathy Diagnosis Obstacles Damaging to Patients' Health

For National Neuropathy Awareness Week (May 13-17), The Neuropathy Association and the Hereditary Neuropathy Foundation Call Attention to the Diagnostic Challenges Hurting Millions of Neuropathy Patients. New York, NY (PRWEB) May 16, 2013 Continued lack of peripheral neuropathy awareness combined with Medicare reimbursement cuts for diagnostic tools are causing major impediments to neuropathy epi...

Novelos Therapeutics Provides Product Pipeline Update

MADISON, Wis., May 16, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today provided an update on its product pipeline, including I-124-CLR1404 (LIGHT) positron emission tomography (PET) imaging agent for solid tumor indications, I-131-CLR1404 (HOT) cancer-targeted molecul...

Ambit Biosciences Announces Pricing of Initial Public Offering

SAN DIEGO, May 16, 2013 /PRNewswire/ -- Ambit Biosciences Corporation today announced the pricing of its initial public offering of 8,125,000 shares of its common stock at $8.00 per share.  Ambit has granted the underwriters a 30-day option to purchase up to an additional 1,218,750 shares at the initial public offering price to cover over-allotments, if any.  Ambit's common stock is...

Market Access Expert Firm, PRMA Consulting, Launches Companion Diagnostics Handbook

Companion diagnostics in oncology – Key questions manufacturers should ask to prepare for market access New York, NY (PRWEB) May 16, 2013 Leading UK company, PRMA Consulting launches PRMA Insights: Market Access Success for Companion Diagnostic–Drug Pairings in Oncology, a unique handbook that addresses the key issues that biopharmaceutical manufacturers should understand when developing new...

Brooklyn Academy Roots Offers 50% Off Pilates Springboard Classes With Pre-Registration

Fitness studio in Jack London Square offering half-off packages for Pilates classes in Oakland when pre-registering before July 1st. Oakland, CA (PRWEB) May 16, 2013 Boutique self-defense and pilates studio in Oakland, Brooklyn Academy Roots, is offering $7-9 per class for a limited time only when purchased before start date of classes. Classes run 45 minutes and will begin July 1st, Monday throu...

Xeljanz, Nouriast priced and set for Japan launch

The latest reimbursement price listing in Japan will pave the way for the first launch anywhere of two drugs, Kyowa Hakko Kirin's Nouriast (istradefylline) for Parkinson's disease and Zeria's Acofide (acotiamide) for functional dyspepsia......

Zane Benefits Publishes New Information on Exchange Navigators

Park City, Utah (PRWEB) May 16, 2013 Today, Zane Benefits, Inc. published new information on Exchange Navigators . Zane Benefits, which provides comprehensive and flexible alternatives to traditional employer sponsored health benefits, is the lea...

Stem Cell Therapeutics to Begin Trading on the U.S. OTCQX Marketplace

TORONTO, ONTARIO -- (Marketwired) -- 05/16/13 -- Stem Cell Therapeutics Corp. (TSX VENTURE: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, today announced that the Company's stock will trade on OTCQX International under the symbol "SCTPF" starting May 20. OTCQX is the premier U.S. Over-The-Counter marketplace, allowing international companies increased access...

VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior Notes

MOUNTAIN VIEW, Calif., May 16, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) announced today the pricing of its offering of $220 million aggregate principal amount of 4.50% convertible senior unsecured notes due May 1, 2020 (the "Notes") in a private placement pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). VIVUS has granted to the initial purchaser...

StoneMor Partners L.P. Announces Pricing of Private $175 Million Debt Offering

LEVITTOWN, Pa., May 16, 2013 (GLOBE NEWSWIRE) -- StoneMor Partners L.P. (NYSE:STON) ("StoneMor") announced today that it and its wholly owned subsidiary, Cornerstone Family Services of West Virginia Subsidiary, Inc. ("CFS West Virginia" and together, the "Issuers"), priced a private offering to eligible purchasers of $175 million aggregate principal amount of Senior Notes due 2021 (the "Notes")....

University General Health System Provides Market Guidance Regarding First Quarter Results

HOUSTON, TX -- (Marketwired) -- 05/16/13 -- University General Health System, Inc. (OTCQB: UGHS), a diversified, integrated multi-specialty health care delivery system, today announced certain preliminary information regarding the quarter ended March 31, 2013. The Company expects to report that first quarter 2013 occupancy at its flagship hospital in Houston exceeded prior-year levels by over 21...

AMI Research Initiates Coverage on Diagnostic Imaging International Corp. With a Speculative Buy Rating of $0.62

LAS VEGAS, NEVADA -- (Marketwired) -- 05/16/13 -- AMI Research, a leading provider of equity research reports and a subsidiary of Hawk Associates Inc., announced today that it has initiated equity research coverage on Diagnostic Imaging International Corp. (OTCQB: DIIG) with a Speculative Buy rating of $0.62 per share. AMI president Peter J. D'Agostino said, "We think DIIG is poised for substan...

Elan Announces Publication of Response Document

Elan Corporation, plc (NYSE : ELN) (Elan) today announces publication of a response document in respect of the Echo Pharma Acquisition Limited (Royalty Pharma) offer made on May 2, 2013. The response document is published in accordance with Rules 25 and 30.3 of the Irish Takeover Rules and the United States tender offer rules. As previously advise...

New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating m...

Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago. "The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatmen...